Last updated: October 13, 2026
Eisai is a Japan-based specialty pharmaceutical company with its strongest competitive positions in Alzheimer’s disease, oncology, neurology and selected gastrointestinal indications. Its market profile is shifting from established products such as Lenvima, Fycompa and Halaven toward Leqembi, the first disease-modifying Alzheimer’s therapy developed by Eisai and Biogen to receive traditional FDA approval.
Leqembi provides Eisai with the highest-value growth opportunity but also carries substantial clinical, reimbursement, manufacturing and safety risks. Lenvima remains the company’s most important commercial asset outside Alzheimer’s disease, supported by a broad oncology label and a global collaboration with Merck. Eisai’s principal strategic weakness is concentration in a small number of partnered and internally developed products, with limited late-stage diversification outside Alzheimer’s and oncology.
What is Eisai’s market position in biopharmaceuticals?
Eisai is a mid-sized global pharmaceutical company with a smaller revenue base than large-cap competitors such as Merck, Roche, Bristol Myers Squibb, Eli Lilly and Novartis. Its strategy emphasizes neurology and oncology rather than broad therapeutic coverage.
Eisai’s core commercial franchises
| Franchise |
Key product |
Primary partner |
Strategic role |
| Alzheimer’s disease |
Leqembi, lecanemab |
Biogen |
Long-term growth driver |
| Oncology |
Lenvima, lenvatinib |
Merck |
Largest established growth franchise |
| Neurology |
Fycompa, perampanel |
Internal and regional partners |
Mature epilepsy product |
| Oncology |
Halaven, eribulin |
Internal and regional partners |
Mature commercial product |
| Insomnia |
Dayvigo, lemborexant |
Regional partners |
Specialty growth product |
| Oncology |
Kisplyx, lenvatinib |
Merck |
Renal-cell carcinoma market extension |
Eisai reported consolidated revenue of approximately ¥741.7 billion for the fiscal year ended March 31, 2024. Lenvima and Leqembi were central to its growth strategy, while older products faced competitive and lifecycle pressure (Eisai Co., Ltd., 2024a).
Eisai’s competitive position depends less on scale than on product ownership, global commercialization rights, regulatory execution and strategic partnerships. The company has used large-pharma collaborations to offset its limited commercial infrastructure. Merck funds and commercializes Lenvima in several markets, while Biogen shares development and commercialization responsibilities for Leqembi.
What products drive Eisai’s revenue and valuation?
Lenvima is Eisai’s primary mature growth asset. Leqembi is the principal valuation driver because Alzheimer’s disease represents a large addressable market and because disease-modifying treatment remains commercially underpenetrated.
Lenvima: established oncology platform
Lenvima is a multikinase inhibitor targeting VEGFR, FGFR, PDGFR-alpha, RET and KIT. The FDA has approved it in several settings, including:
- Differentiated thyroid cancer
- Renal cell carcinoma in combination with everolimus
- Endometrial carcinoma in combination with pembrolizumab
- Unresectable hepatocellular carcinoma in the first-line setting
The pembrolizumab combination with Merck is the most important commercial expansion. The partnership combines Eisai’s small-molecule oncology asset with Merck’s immuno-oncology platform and global commercial reach.
Lenvima faces competition from checkpoint inhibitors, VEGF-targeted therapies, tyrosine kinase inhibitors and combination regimens. Its durability depends on maintaining clinical differentiation, extending use into new tumor types and preserving pricing despite competitive treatment sequencing.
Leqembi: Alzheimer’s disease growth platform
Leqembi is an anti-amyloid beta monoclonal antibody indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage of disease with confirmed amyloid pathology. The FDA granted traditional approval in July 2023 based on the CLARITY AD trial (U.S. Food and Drug Administration, 2023a).
The product reduced clinical decline in the trial but requires intravenous infusions, amyloid confirmation and monitoring for amyloid-related imaging abnormalities, commonly known as ARIA. These requirements increase treatment-center capacity needs and limit rapid population-wide adoption.
Medicare coverage improved after traditional FDA approval. The Centers for Medicare & Medicaid Services stated that Medicare would cover FDA-approved anti-amyloid monoclonal antibodies when providers participate in appropriate data-collection arrangements (Centers for Medicare & Medicaid Services, 2023).
How does Eisai compare with competitors in Alzheimer’s disease?
Eisai has a first-mover commercial position in disease-modifying Alzheimer’s treatment, but its competitive lead is not permanent.
| Company |
Product |
Mechanism |
FDA status through mid-2024 |
Competitive issue |
| Eisai/Biogen |
Leqembi |
Anti-amyloid antibody |
Traditional approval |
Infusion, ARIA, diagnosis and monitoring |
| Eli Lilly |
Kisunla, donanemab |
Anti-amyloid antibody |
FDA review underway through mid-2024 |
Potential dosing and clearance advantages |
| Biogen |
Aduhelm, aducanumab |
Anti-amyloid antibody |
Accelerated approval |
Limited coverage and commercial withdrawal |
| Roche |
Gantenerumab programs |
Anti-amyloid antibody |
Development-stage |
Clinical and regulatory execution |
| Novo Nordisk |
GLP-1 programs |
Metabolic pathway |
Not an established Alzheimer’s therapy |
Indirect competitive research risk |
Lilly’s donanemab program is the most direct competitive threat. A product with a different dosing schedule, faster amyloid clearance or lower treatment burden could reduce Leqembi’s market share. Leqembi’s commercial advantage depends on earlier treatment, physician familiarity, reimbursement, infusion access and a favorable long-term safety record.
What patents protect Eisai’s major drugs?
Eisai’s patent strength is asset-specific. Lenvima has the broadest commercial and lifecycle exposure because it is marketed across multiple indications and territories. Leqembi has biologic composition, treatment-method and manufacturing protection, but its effective exclusivity depends on patent-term adjustment, regulatory exclusivity, biosimilar rules and the timing of competing antibodies.
Patent and exclusivity profile
| Product |
Protection category |
Main risk |
| Leqembi |
Antibody composition, use patents, manufacturing and formulation claims |
Biosimilar or follow-on antibody entry after regulatory and patent expiry |
| Lenvima |
Small-molecule composition, polymorph, formulation and method-of-use claims |
Generic substitution and patent litigation |
| Fycompa |
Small-molecule and method-of-use protection |
Mature-product generic entry |
| Dayvigo |
Composition, formulation and method-of-use claims |
Sleep-drug competition and generic timing |
| Halaven |
Composition, formulation and method-of-use protection |
Mature oncology product erosion |
Patent term for a product cannot be determined from the FDA approval date alone. The relevant analysis requires the granted claims, patent-term adjustment, terminal disclaimers, pediatric extensions, regulatory exclusivity and jurisdiction-specific litigation outcomes.
What formulations are protected by Eisai’s patents?
Leqembi’s commercial protection is expected to include antibody composition claims, treatment claims directed to patients with confirmed amyloid pathology and claims covering administration regimens. Formulation and manufacturing claims can create additional barriers, but they typically do not prevent all follow-on biologic competition.
Lenvima’s protection is more exposed to conventional generic strategies because it is an orally administered small molecule. Generic manufacturers can challenge composition, polymorph, formulation and method-of-use patents through an abbreviated new drug application and Paragraph IV certification.
When does Eisai lose exclusivity on its leading drugs?
The practical loss-of-exclusivity date differs by product, jurisdiction and patent claim.
Leqembi exclusivity timeline
- 2021: FDA grants accelerated approval for aducanumab, increasing regulatory focus on anti-amyloid therapies.
- January 2023: FDA grants accelerated approval to Leqembi.
- July 2023: FDA grants traditional approval to Leqembi after confirmatory clinical data.
- 2023 onward: Medicare coverage expands for FDA-approved anti-amyloid monoclonal antibodies under evidence-development requirements.
- Mid-2024: Eisai continues development of subcutaneous and simplified administration options.
Leqembi has twelve years of U.S. reference-product exclusivity under the biologics framework, subject to applicable statutory rules. Patent protection may extend beyond regulatory exclusivity, but biosimilar entry will depend on the final patent estate and litigation.
Lenvima exclusivity timeline
Lenvima is further along in its lifecycle. U.S. and international exclusivity is governed by multiple patents and indication-specific claims. The product has already encountered generic competition in certain markets and remains exposed to future generic challenges where relevant patent claims have expired or been invalidated.
The Merck collaboration may extend commercial value through new indications, but new indications do not necessarily restore broad composition-patent exclusivity. Method-of-use patents are narrower and easier for generic applicants to design around.
Which companies are challenging Eisai’s market position?
Eli Lilly is the most direct challenger to Leqembi in Alzheimer’s disease. Merck’s Keytruda combinations and Bristol Myers Squibb’s Opdivo-based regimens compete with Lenvima in oncology, while Pfizer, Johnson & Johnson, Novartis and generic manufacturers compete across Eisai’s mature portfolio.
Competitive threats by therapeutic area
| Area |
Primary competitors |
Threat type |
| Alzheimer’s disease |
Eli Lilly |
Direct product competition |
| Renal-cell carcinoma |
Bristol Myers Squibb, Roche, Pfizer |
Regimen and sequencing competition |
| Endometrial cancer |
Merck, Roche, AstraZeneca |
Combination therapy competition |
| Epilepsy |
UCB, generic manufacturers |
Product substitution and price erosion |
| Insomnia |
Idorsia, generic sedative products |
Class and reimbursement competition |
| Breast cancer |
Generic eribulin and branded oncology agents |
Lifecycle erosion |
Eisai’s partnerships reduce some competitive disadvantages. Merck contributes global oncology infrastructure, while Biogen adds neurology commercialization capabilities. The trade-off is shared economics and reduced control over pricing, development priorities and commercial execution.
What is the FDA and Orange Book status of Eisai products?
Leqembi is a biologic and is not listed in the Orange Book in the same manner as an approved small-molecule drug. Its follow-on competition is governed primarily by the Public Health Service Act and the biosimilar pathway.
Lenvima, Fycompa, Dayvigo and Halaven are small-molecule products subject to the abbreviated new drug application framework. Relevant patents may be listed in the FDA Orange Book if they meet FDA listing requirements. Orange Book listings can support notice-based Paragraph IV litigation, but listing does not guarantee that every patent will survive validity or infringement challenges (U.S. Food and Drug Administration, 2023b).
What generic entry risks exist for Eisai?
Eisai faces the highest generic-entry risk from older oral products. Generic erosion can be rapid when multiple manufacturers receive approval and no enforceable patent or regulatory exclusivity remains.
Generic launch scenarios
| Scenario |
Likely effect on Eisai |
| No Paragraph IV filing |
Gradual erosion after patent expiry |
| Paragraph IV challenge without settlement |
Litigation before commercial launch |
| Paragraph IV settlement with delayed entry |
Predictable erosion after agreed date |
| At-risk generic launch |
Rapid revenue loss and potential damages litigation |
| Authorized generic or license |
Controlled price erosion and retained supply economics |
Public Eisai disclosures through fiscal 2023 identify lifecycle management and patent enforcement as important to product preservation, but do not establish a single company-wide generic settlement strategy (Eisai Co., Ltd., 2024a).
How strong is Eisai’s patent estate?
Eisai’s patent estate is strongest for Leqembi and Lenvima, but the quality differs by asset.
Leqembi has the advantage of biologic manufacturing complexity, clinical-development requirements and a high evidentiary burden for biosimilar approval. Its risks include ARIA-related safety concerns, limited treatment-center capacity and the possibility that competing antibodies offer more convenient treatment.
Lenvima has broad indication coverage and combination-use patents, but its small-molecule profile makes it more vulnerable to generic substitution. The strongest claims are those that remain enforceable and difficult to design around. Method-of-use claims can protect revenue after composition claims expire, but their commercial value depends on prescribing behavior and the scope of the approved label.
Eisai’s patent strength is therefore medium-to-strong at the portfolio level, with the highest strategic value concentrated in Leqembi’s biologic and clinical-use protection and Lenvima’s partnered oncology platform.
What patent litigation and settlement risks affect Eisai?
The most material legal risks are likely to arise from:
- Paragraph IV challenges to small-molecule products.
- Orange Book disputes over listed Lenvima, Fycompa or Dayvigo patents.
- Biosimilar patent litigation involving Leqembi.
- Method-of-use claims covering combination regimens.
- Manufacturing and formulation claims that affect follow-on products.
A successful generic challenge could reduce revenue faster than ordinary market competition. A successful patent-enforcement case could preserve revenue but increase legal costs and delay generic entry. Settlement agreements can provide commercial certainty but may reduce the duration of effective exclusivity compared with full litigation success.
What licensing deals shape Eisai’s strategy?
Eisai’s two most important strategic transactions are its collaboration with Merck for Lenvima and its collaboration with Biogen for Leqembi.
Eisai-Merck Lenvima collaboration
The alliance combines Lenvima with Merck’s pembrolizumab. Merck contributes Keytruda’s global oncology presence and development infrastructure. Eisai retains a major role in Lenvima development and economics, while the collaboration broadens the product’s clinical reach.
Eisai-Biogen Leqembi collaboration
The Eisai-Biogen agreement combines Eisai’s Alzheimer’s research and development leadership with Biogen’s experience in neurodegenerative disease commercialization. Shared development and commercialization reduce Eisai’s standalone execution burden but also divide revenue and strategic control.
What is Eisai’s revenue exposure to Leqembi and Lenvima?
Lenvima is the more established revenue contributor. Leqembi is the more important future growth asset.
The financial sensitivity is asymmetric:
- Lenvima faces mature-product erosion but generates established oncology revenue.
- Leqembi requires substantial investment before reaching large-scale commercial penetration.
- Leqembi sales depend on diagnosis rates, amyloid confirmation, infusion capacity, reimbursement and safety monitoring.
- Partnership economics reduce Eisai’s gross revenue capture relative to a wholly owned product.
- A competing Alzheimer’s antibody could compress Leqembi’s peak-sales potential.
Eisai’s valuation is therefore highly sensitive to the pace of Leqembi uptake, the durability of Lenvima revenue and the company’s ability to replace mature-product sales with new assets.
What generic and biosimilar launch scenarios should investors monitor?
The most important monitoring points are:
- FDA Orange Book patent listings for Eisai’s small-molecule products.
- Paragraph IV certifications and related district-court complaints.
- Patent-term-adjustment calculations.
- ANDA approvals and tentative approvals.
- Biosimilar applications for Leqembi.
- FDA supplemental approvals for subcutaneous or lower-burden administration.
- Medicare coverage implementation.
- New Alzheimer’s disease competitors, especially donanemab.
- Lenvima combination-label expansion and post-marketing data.
Key Takeaways
- Eisai’s market position is concentrated in Alzheimer’s disease and oncology.
- Leqembi is the company’s main long-term growth driver and its most important strategic asset.
- Lenvima remains the principal established revenue franchise, supported by the Merck collaboration.
- Eli Lilly’s donanemab is the most direct competitive threat to Leqembi.
- Small-molecule products such as Lenvima, Fycompa, Dayvigo and Halaven face greater generic-entry risk than Leqembi.
- Leqembi is protected by biologic exclusivity, patents and manufacturing complexity, but commercial adoption is constrained by infusion and ARIA-monitoring requirements.
- Eisai’s patent estate is strongest at the asset level rather than across the entire portfolio.
- The company’s principal commercial risk is dependence on a small number of partnered products and the transition from mature products to Leqembi growth.
FAQs
How does Eisai compare with Lilly in Alzheimer’s disease?
Eisai has commercialized Leqembi earlier, while Lilly has a direct competing anti-amyloid program with donanemab. Competition will center on clinical outcomes, dosing frequency, ARIA risk, amyloid-clearance speed, reimbursement and treatment-center capacity.
Is Leqembi a biologic or a small-molecule drug?
Leqembi is a monoclonal antibody biologic. It is regulated under the biologics framework and is not subject to ordinary small-molecule ANDA substitution.
Does Eisai own Lenvima outright?
Eisai discovered and owns Lenvima, but commercial rights and development economics are governed in part by the collaboration with Merck.
What is Eisai’s largest patent risk?
The largest near-term patent risk is generic erosion of mature small-molecule products. The largest long-term risk is a successful biosimilar or follow-on challenge to Leqembi after applicable exclusivity and patent protections expire.
Which Eisai product has the strongest growth outlook?
Leqembi has the strongest growth outlook, while Lenvima has the stronger established commercial base. Leqembi also has greater execution, safety, reimbursement and competitive risk.
References
Centers for Medicare & Medicaid Services. (2023). Coverage decision memo for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. https://www.cms.gov/
Eisai Co., Ltd. (2024a). Integrated report 2024. https://www.eisai.com/
U.S. Food and Drug Administration. (2023a). FDA grants traditional approval for Eisai’s Leqembi. https://www.fda.gov/
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/ alent Goodman.
